Applied DNA Sciences Files Q3 2024 10-Q
Ticker: BNBX · Form: 10-Q · Filed: Aug 8, 2024 · CIK: 744452
Sentiment: neutral
Topics: 10-Q, financials, SEC filing
Related Tickers: APDN
TL;DR
APDN 10-Q filed: Latest financials for Q3 2024 are in. Check for updates on cash burn & revenue.
AI Summary
Applied DNA Sciences Inc. reported its financial results for the quarter ending June 30, 2024. The company's fiscal year ends on September 30th. The filing details various financial activities and disclosures, including information related to common stock and retained earnings as of June 30, 2024.
Why It Matters
This 10-Q filing provides investors with the latest financial performance and operational updates for Applied DNA Sciences Inc., crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a publicly traded company filing a 10-Q, there are inherent risks associated with financial reporting and market performance.
Key Numbers
- 001-36745 — SEC File Number (Identifies the company's filing with the SEC.)
- 0930 — Fiscal Year End (Indicates the end of the company's annual accounting period.)
Key Players & Entities
- APPLIED DNA SCIENCES INC (company) — Filer
- 20240630 (date) — Period of Report
- 20240808 (date) — Filed as of Date
- STONY BROOK, NY 11790 (location) — Business Address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, indicating the quarter ending June 30, 2024.
When was this 10-Q filing submitted?
The filing was submitted on 20240808.
What is the company's primary business address?
The company's business address is 50 Health Sciences Drive, Stony Brook, NY 11790.
What is the company's SEC file number?
The SEC File Number is 001-36745.
When does Applied DNA Sciences Inc. end its fiscal year?
Applied DNA Sciences Inc.'s fiscal year ends on 0930.
Filing Stats: 4,404 words · 18 min read · ~15 pages · Grade level 19.5 · Accepted 2024-08-08 16:11:53
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- apdn-20240630x10q.htm (10-Q) — 1657KB
- apdn-20240630xex31d1.htm (EX-31.1) — 12KB
- apdn-20240630xex31d2.htm (EX-31.2) — 12KB
- apdn-20240630xex32d1.htm (EX-32.1) — 6KB
- apdn-20240630xex32d2.htm (EX-32.2) — 6KB
- 0001410578-24-001226.txt ( ) — 7278KB
- apdn-20240630.xsd (EX-101.SCH) — 49KB
- apdn-20240630_cal.xml (EX-101.CAL) — 43KB
- apdn-20240630_def.xml (EX-101.DEF) — 192KB
- apdn-20240630_lab.xml (EX-101.LAB) — 352KB
- apdn-20240630_pre.xml (EX-101.PRE) — 283KB
- apdn-20240630x10q_htm.xml (XML) — 1447KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
- Condensed Consolidated Financial Statements (unaudited)
Item 1 - Condensed Consolidated Financial Statements (unaudited) 1
- Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 22
- Quantitative and Qualitative Disclosures About Market Risk
Item 3 - Quantitative and Qualitative Disclosures About Market Risk 35
- Controls and Procedures
Item 4 - Controls and Procedures 35
- OTHER INFORMATION
PART II - OTHER INFORMATION
– Legal Proceedings
Item 1 – Legal Proceedings 36
– Risk Factors
Item 1A – Risk Factors 36
– Unregistered Sales of Equity Securities and Use of Proceeds
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 38
– Defaults Upon Senior Securities
Item 3 – Defaults Upon Senior Securities 38
– Mine Safety Disclosures
Item 4 – Mine Safety Disclosures 38
– Other Information
Item 5 – Other Information 38
– Exhibits
Item 6 – Exhibits 39 Table of Contents
- Financial Information
Part I - Financial Information
- Financial Statements
Item 1 - Financial Statements APPLIED DNA SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, September 30, 2024 2023 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 10,442,131 $ 7,151,800 Accounts receivable, net of allowance for credit losses of $ 75,000 at June 30, 2024 and September 30, 2023, respectively 513,871 255,502 Inventories 469,871 330,027 Prepaid expenses and other current assets 416,427 389,241 Total current assets 11,842,300 8,126,570 Property and equipment, net 530,735 838,270 Other assets: Restricted cash 750,000 750,000 Intangible assets 2,698,975 2,698,975 Operating right of use asset 868,081 1,237,762 Total assets $ 16,690,091 $ 13,651,577 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued liabilities $ 2,440,688 $ 2,270,388 Operating lease liability, current 533,679 498,598 Deferred revenue 51,285 76,435 Total current liabilities 3,025,652 2,845,421 Long term accrued liabilities 31,467 31,467 Deferred revenue, long term 194,000 194,000 Operating lease liability, long term 334,402 739,162 Deferred tax liability, net 684,115 684,115 Warrants classified as a liability 186,000 4,285,000 Total liabilities 4,455,636 8,779,165 Commitments and contingencies (Note G) Applied DNA Sciences, Inc. stockholders' equity: Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - shares issued and outstanding as of June 30, 2024 and September 30, 2023, respectively — — Series A Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - issued and outstanding as of June 30, 2024 and September 30, 2023, respectively — — Series B Preferred stock, par value $ 0.001 per share; 10,000,000 shares authorized; - 0 - issued and outstanding as of June 30, 2024 and September 30, 2023, respectively — — Common stock, par va